TY - JOUR
T1 - Treatment for multiple periorbital eccrine hidrocystomas
T2 - Botulinum toxin A
AU - Woolery-Lloyd, Heather
AU - Rajpara, Vidya
AU - Nijhawan, Rajiv I.
PY - 2009/1/1
Y1 - 2009/1/1
N2 - Hidrocystomas are relatively common cystic lesions that can display either apocrine or eccrine differentiation. While numerous treatment modalities exist for solitary hidrocystomas including simple excision, electrodesiccation, and CO2 laser, treatment of multiple hidrocystomas can be challenging. A 38-year-old, black female with a 23-year history of multiple periorbital cystic nodules presented to the clinic with the complaint of lesions that were increasing in size and number. Prior treatment included excision resulting in scarring without signifi cant clinical improvement. Initially, incision and drainage was performed with fl attening of the cysts; however, the cystic nodules refi lled to baseline by 6 weeks. Subsequently, intralesional botulinum toxin type A was offered as an alternate therapy in conjunction with incision and drainage. The patient reported sustained fl attening of the lesions at both 1-month and 4-month follow-up appointments. Intralesional botulinum toxin A offers a novel treatment for patients with multiple hidrocystomas that have failed other therapies.
AB - Hidrocystomas are relatively common cystic lesions that can display either apocrine or eccrine differentiation. While numerous treatment modalities exist for solitary hidrocystomas including simple excision, electrodesiccation, and CO2 laser, treatment of multiple hidrocystomas can be challenging. A 38-year-old, black female with a 23-year history of multiple periorbital cystic nodules presented to the clinic with the complaint of lesions that were increasing in size and number. Prior treatment included excision resulting in scarring without signifi cant clinical improvement. Initially, incision and drainage was performed with fl attening of the cysts; however, the cystic nodules refi lled to baseline by 6 weeks. Subsequently, intralesional botulinum toxin type A was offered as an alternate therapy in conjunction with incision and drainage. The patient reported sustained fl attening of the lesions at both 1-month and 4-month follow-up appointments. Intralesional botulinum toxin A offers a novel treatment for patients with multiple hidrocystomas that have failed other therapies.
UR - http://www.scopus.com/inward/record.url?scp=60849099621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60849099621&partnerID=8YFLogxK
M3 - Article
C2 - 19180900
AN - SCOPUS:60849099621
SN - 1545-9616
VL - 8
SP - 71
EP - 73
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 1
ER -